{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:57:09Z","timestamp":1794459429239,"version":"4.9.1"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.humpath.2024.105679","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T17:09:33Z","timestamp":1730567373000},"page":"105679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Clinical use of circulating tumor DNA analysis in patients with lymphoma"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-375X","authenticated-orcid":false,"given":"Bettina","family":"Bisig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"de Leval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2024.105679_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100399","article-title":"Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer","volume":"7","author":"Heitzer","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.humpath.2024.105679_bib2","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.23.00638","article-title":"Targeted therapy in metastatic breast cancer expert P. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update","volume":"41","author":"Burstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2024.105679_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JOP.19.00691","article-title":"Potential of circulating tumor DNA for the management of patients with lymphoma","volume":"16","author":"Huet","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.humpath.2024.105679_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-050520-044652","article-title":"Molecular monitoring of lymphomas","volume":"18","author":"Schroers-Martin","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.humpath.2024.105679_bib8","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.humpath.2024.105679_bib10","first-page":"241","article-title":"[Nuclear acids in human blood plasma]","volume":"142","author":"Mandel","year":"1948","journal-title":"C R Seances Soc Biol Fil"},{"key":"10.1016\/j.humpath.2024.105679_bib11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","article-title":"Life and death of circulating cell-free DNA","volume":"20","author":"Kustanovich","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.humpath.2024.105679_bib12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2024.105679_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"Sanchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2024.105679_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.humpath.2024.105679_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2024.105679_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.humpath.2024.105679_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1373\/clinchem.2018.298323","article-title":"Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA","volume":"65","author":"Meddeb","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.humpath.2024.105679_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41598-022-27216-5","article-title":"Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows","volume":"13","author":"Lehle","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2024.105679_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070617","article-title":"How to obtain a high quality ctDNA in lymphoma patients: preanalytical tips and tricks","volume":"14","author":"Bourbon","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.humpath.2024.105679_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cas.13450","article-title":"Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma","volume":"109","author":"Hattori","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2024.105679_bib24","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mdx501","article-title":"Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review","volume":"28","author":"Garcia-Foncillas","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.humpath.2024.105679_bib111","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","article-title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","volume":"8","author":"Bohers","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.humpath.2024.105679_bib112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2024.105679_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib96","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"issue":"27","key":"10.1016\/j.humpath.2024.105679_bib113","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib25","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2024.105679_bib95","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib27","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1016\/j.humpath.2024.105679_bib114","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib54","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","article-title":"Inferring gene expression from cell-free DNA fragmentation profiles","volume":"40","author":"Esfahani","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.humpath.2024.105679_bib115","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","article-title":"Detection and characterization of lung cancer using cell-free DNA fragmentomes","volume":"12","author":"Mathios","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2024.105679_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3324\/haematol.2020.268813","article-title":"Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential","volume":"107","author":"Raman","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2024.105679_bib78","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","article-title":"The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA","volume":"5","author":"Buedts","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105679_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmoldx.2024.01.014","article-title":"Assay validation of cell-free DNA shallow whole-genome sequencing to determine tumor fraction in advanced cancers","volume":"26","author":"Rickles-Young","year":"2024","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2024.105679_bib41","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","article-title":"Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease","volume":"9","author":"Moss","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2024.105679_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13148-018-0487-y","article-title":"A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples","volume":"10","author":"Gallardo-Gomez","year":"2018","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.humpath.2024.105679_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13148-020-00973-8","article-title":"5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients","volume":"13","author":"Chen","year":"2021","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.humpath.2024.105679_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41525-021-00179-8","article-title":"Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma","volume":"6","author":"Chiu","year":"2021","journal-title":"NPJ Genom Med"},{"issue":"5","key":"10.1016\/j.humpath.2024.105679_bib116","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-21-3762","article-title":"Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis","volume":"28","author":"Berchuck","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2024.105679_bib117","doi-asserted-by":"crossref","first-page":"596078","DOI":"10.3389\/fgene.2020.596078","article-title":"Genome-Wide Analysis of Cell-Free DNA Methylation Profiling for the Early Diagnosis of Pancreatic Cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.humpath.2024.105679_bib118","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.humpath.2024.105679_bib119","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-020-0932-2","article-title":"Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes","volume":"26","author":"Nassiri","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2024.105679_bib46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41587-020-00775-6","article-title":"ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin","volume":"39","author":"Sadeh","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.humpath.2024.105679_bib120","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","article-title":"Liquid biopsy epigenomic profiling for cancer subtyping","volume":"29","author":"Baca","year":"2023","journal-title":"Nat Med."},{"issue":"5","key":"10.1016\/j.humpath.2024.105679_bib121","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/1878-0261.13394","article-title":"Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients","volume":"17","author":"Trier Maansson","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib53","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1038\/s41467-019-12714-4","article-title":"Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection","volume":"10","author":"Ulz","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2024.105679_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13059-022-02710-1","article-title":"Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing","volume":"23","author":"Katsman","year":"2022","journal-title":"Genome Biol"},{"key":"10.1016\/j.humpath.2024.105679_bib122","doi-asserted-by":"crossref","first-page":"958673","DOI":"10.3389\/fonc.2022.958673","article-title":"Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia","volume":"12","author":"Sampathi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib56","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1182\/blood-2023-190154","article-title":"A novel approach: nanopore sequencing of native cell-free DNA in diffuse-large B-cell lymphoma patients","volume":"142","author":"Erblich","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.humpath.2024.105679_bib123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-023-01178-3","article-title":"Single-molecule methylation profiles of cell-free DNA in cancer with nanopore sequencing","volume":"15","author":"Lau","year":"2023","journal-title":"Genome Med."},{"key":"10.1016\/j.humpath.2024.105679_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00401-024-02793-z","article-title":"Rapid brain lymphoma diagnostics through nanopore sequencing of cytology-negative cerebrospinal fluid","volume":"148","author":"Hench","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.humpath.2024.105679_bib21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2024.105679_bib22","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.1133470100","article-title":"Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations","volume":"100","author":"Dressman","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2024.105679_bib26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.humpath.2024.105679_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40291-021-00534-6","article-title":"Leveraging the fragment length of circulating tumour DNA to improve molecular profiling of solid tumour malignancies with next-generation sequencing: a pathway to advanced non-invasive diagnostics in precision oncology?","volume":"25","author":"Underhill","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.humpath.2024.105679_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/gm477","article-title":"Circulating tumor cells and DNA as liquid biopsies","volume":"5","author":"Heitzer","year":"2013","journal-title":"Genome Med"},{"key":"10.1016\/j.humpath.2024.105679_bib30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2024.105679_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166126","article-title":"Vidjil: a web platform for analysis of high-throughput repertoire sequencing","volume":"11","author":"Duez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2024.105679_bib34","first-page":"4198","article-title":"Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL","volume":"5","author":"Miljkovic","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105679_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4143\/crt.2022.017","article-title":"Circulating tumor DNA-based genotyping and monitoring for predicting disease relapses of patients with peripheral T-cell lymphomas","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.humpath.2024.105679_bib36","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jmoldx.2021.04.013","article-title":"Detection of gene fusion transcripts in peripheral T-cell lymphoma using a multiplexed targeted sequencing assay","volume":"23","author":"Drieux","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2024.105679_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16261","article-title":"Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors","volume":"9","author":"Albitar","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.humpath.2024.105679_bib38","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","article-title":"Navigating the DNA methylation landscape of cancer","volume":"37","author":"Nishiyama","year":"2021","journal-title":"Trends Genet"},{"key":"10.1016\/j.humpath.2024.105679_bib39","article-title":"Cell-free DNA methylation profiling analysis-technologies and bioinformatics","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.humpath.2024.105679_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tig.2008.01.006","article-title":"The methylome: approaches for global DNA methylation profiling","volume":"24","author":"Beck","year":"2008","journal-title":"Trends Genet"},{"key":"10.1016\/j.humpath.2024.105679_bib43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/ng1598","article-title":"Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells","volume":"37","author":"Weber","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2024.105679_bib44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nprot.2012.012","article-title":"Methylome analysis using MeDIP-seq with low DNA concentrations","volume":"7","author":"Taiwo","year":"2012","journal-title":"Nat Protoc"},{"key":"10.1016\/j.humpath.2024.105679_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43520-0","article-title":"Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma","volume":"13","author":"Van den Ackerveken","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2024.105679_bib48","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1158\/1538-7445.AM2024-5128","article-title":"Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients: translational analyses from CAIRE trial","volume":"84","author":"Salani","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2024.105679_bib49","article-title":"Circulating DNA fragmentomics and cancer screening","volume":"3","author":"Thierry","year":"2023","journal-title":"Cell Genom"},{"key":"10.1016\/j.humpath.2024.105679_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-bioeng-110222-111259","article-title":"Liquid biopsy based on cell-free DNA and RNA","volume":"26","author":"Loy","year":"2024","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.humpath.2024.105679_bib51","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-19-0622","article-title":"Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation","volume":"10","author":"Jiang","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2024.105679_bib52","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2024.105679_bib93","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib94","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.humpath.2024.105679_bib70","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-05782-0","article-title":"Circulating tumor DNA assisting lymphoma genetic feature profiling and identification","author":"Wang","year":"20241034135","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2024.105679_bib104","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/bloodadvances.2021004528","article-title":"Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab","volume":"5","author":"Bruscaggin","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105679_bib106","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib72","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10428194.2021.2010060","article-title":"Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study","volume":"63","author":"Camus","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2024.105679_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12071575","article-title":"Cell-free DNA for genomic analysis in primary mediastinal large B-cell lymphoma","volume":"12","author":"Rivas-Delgado","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.humpath.2024.105679_bib124","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-142349","article-title":"Ctdna monitoring in predicting relapse of primary mediastinal B-cell lymphoma","volume":"136","author":"Pang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","article-title":"Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis","volume":"7","author":"Rimelen","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.humpath.2024.105679_bib59","first-page":"1598","article-title":"The molecular hallmarks of primary and secondary vitreoretinal lymphoma","volume":"6","author":"Bonzheim","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105679_bib60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024023832","article-title":"Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma","author":"Gupta","year":"20241441093","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib97","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105679_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fernandez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2024.105679_bib88","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Jimenez-Ubieto","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2024.105679_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/joim.13674","article-title":"Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma","volume":"294","author":"Nagy","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.humpath.2024.105679_bib98","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105679_bib99","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/ijlh.13498","article-title":"Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas","volume":"43","author":"Zhang","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.humpath.2024.105679_bib83","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18824","article-title":"Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma","volume":"202","author":"Wei","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2024.105679_bib84","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hon.3164_240","article-title":"Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T-cell lymphoma","volume":"41","author":"Liang","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib82","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00277-017-3038-2","article-title":"Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma","volume":"96","author":"Sakata-Yanagimoto","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2024.105679_bib85","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/hon.3164_241","article-title":"Cell-free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study","volume":"41","author":"Sako","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib74","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.humpath.2024.105679_bib76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2024.105679_bib77","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.humpath.2024.105679_bib58","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1182\/bloodadvances.2021004512","article-title":"Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma","volume":"5","author":"Olszewski","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.105679_bib61","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2024.105679_bib62","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12883-024-03761-6","article-title":"Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers","volume":"24","author":"Loser","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.humpath.2024.105679_bib63","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/S2352-3026(24)00104-2","article-title":"Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88(Leu265Pro) and IL-10","volume":"11","author":"Calimeri","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.humpath.2024.105679_bib65","doi-asserted-by":"crossref","first-page":"48157","DOI":"10.18632\/oncotarget.18325","article-title":"Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma","volume":"8","author":"Fontanilles","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2024.105679_bib66","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3324\/haematol.2018.206177","article-title":"Liquid biopsy in lymphoma","volume":"104","author":"Rossi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2024.105679_bib67","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2024.105679_bib68","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2024.105679_bib71","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2019-132069","article-title":"Towards non-invasive classification of DLBCL genetic subtypes by ctdna profiling","volume":"134","author":"Esfahani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib80","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib81","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib86","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.3324\/haematol.2023.282716","article-title":"Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions","volume":"108","author":"Bisig","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2024.105679_bib90","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2024.105679_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040650","article-title":"Spatial heterogeneity in large resected diffuse large B-cell lymphoma bulks analysed by massively parallel sequencing of multiple synchronous biopsies","volume":"13","author":"Magnes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.humpath.2024.105679_bib92","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1080\/10428194.2023.2220454","article-title":"Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma","volume":"64","author":"Hersby","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2024.105679_bib101","article-title":"Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer\/T cell lymphoma","volume":"4","author":"Tian","year":"2023","journal-title":"Cell Rep Med"},{"issue":"Suppl 1","key":"10.1016\/j.humpath.2024.105679_bib102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hon.2587","article-title":"Liquid biopsy in non-Hodgkin's lymphoma","volume":"37","author":"Melani","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib103","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2022-167936","article-title":"MRD-negativity as a potential surrogate endpoint after frontline DLBCL therapy: pooled analysis of trials & implications for clinical trial design","volume":"140","author":"Roschewski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105679_bib107","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11864-024-01201-8","article-title":"Circulating tumor DNA in diffuse large B-cell lymphoma: from bench to bedside?","volume":"25","author":"Cherng","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.humpath.2024.105679_bib108","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminhematol.2023.06.003","article-title":"Clinical applications of circulating tumor DNA in indolent B-cell lymphomas","volume":"60","author":"Lakhotia","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.humpath.2024.105679_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.humpath.2024.105679_bib110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724001886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724001886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T21:41:40Z","timestamp":1741297300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724001886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":124,"alternative-id":["S0046817724001886"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105679","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical use of circulating tumor DNA analysis in patients with lymphoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105679"}}